Home › Trials › NCT04529122

Worldwide cancer registry for patients with solid tumors and next-generation sequencing

A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)

Observational Hoffmann-La Roche · NCT04529122

This study is trying to see how the results from advanced genetic testing can help improve treatment and outcomes for people with solid tumors.

Quick facts

Study typeObservational
Enrollment15000 (estimated)
Ages18 Years and up
SexAll
SponsorHoffmann-La Roche Industry-sponsored
Locations138 sites (Buenos Aires and 137 other locations)
Trial IDNCT04529122 on ClinicalTrials.gov

What this trial studies

WAYFIND-R is a registry designed to collect high-quality real-world data that connects next-generation sequencing (NGS) results with treatment outcomes in patients diagnosed with solid tumors. The registry aims to support clinical and epidemiological research, enhance understanding of health outcomes, and characterize treatment courses for these patients. By enrolling participants who have undergone NGS testing, the study seeks to provide valuable insights into cancer care processes and outcomes.

Who should consider this trial

Good fit: Ideal candidates for this registry are adults diagnosed with any type of solid tumor cancer who have undergone NGS testing within the last three months.

Not a fit: Patients with a prior or current diagnosis of hematological malignancies will not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could improve understanding of treatment effectiveness and outcomes for patients with solid tumors, leading to better personalized care.

How similar studies have performed: Other studies utilizing real-world data and NGS have shown promise in improving cancer treatment outcomes, indicating that this approach is supported by previous successes.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participant is an adult (according to the age of majority as defined by local regulations)
* Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
* Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
* Informed consent has been obtained from the participant or legally authorized representative, as per local regulations

Exclusion Criteria:

-Participant has a prior or current diagnosis of haematological malignancy

Where this trial is running

Buenos Aires and 137 other locations

+88 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Solid Tumours
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.